RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai’s Ascentage Pharma announced a five-year strategic collaboration with The University of Texas MD Anderson Cancer Center for clinical development of five potential cancer therapies. The five candidates, which are apoptosis-targeted and tyrosine kinase inhibitors, were discovered by Ascentage’s Protein-Protein Interaction platform. They will be studied as single-agent therapies and in combination with approved or investigational drugs as treatments for various hematologic malignancies.
Source: China Biotoday
